Pub Date : 2026-03-01Epub Date: 2026-01-07DOI: 10.1016/j.jceh.2025.103468
Narendra S Choudhary, Ajay Duseja, Arka De, Manu Mehta, S P Singh, Prajna Anirvan, Shrikant Mukewar, Sourabh Mukewar, Shalimar, Sanjib Kar, Omesh Goyal, Rakhi Maiwall, Jayanthi Venkataraman, Krishnadas Devadas, V K Dixit, Varun Mehta, Piyush Ranjan, Aabha Nagral, Anil Arora, Arun Valsan, Sunil Dadhich, Brij Sharma, Rohit Gupta, Sandeep Nijhawan, Akash Roy, Dibyalochan Praharaj, P N Rao, Akash Shukla, Rajiv Mehta, Pankaj Asati, Sanjeev Saigal, K Narayanasamy, Mallika Bhattacharya, V G M Prasad, Abraham Koshy, Mukul Rastogi, Seema Alam, Arun J Sanyal
Background: The association between diabetes mellitus and liver fibrosis is well studied in patients with nonalcoholic fatty liver disease (NAFLD). With the recent change in nomenclature and definition, similar data are not available in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The present study aims to analyse the association of advanced fibrosis (stage 3 or 4 on liver biopsy) and type 2 diabetes mellitus (T2DM) in patients with MASLD.
Methods: In an ongoing multicentre study of the Indian Consortium on MASLD(ICOM-D) including 30 centres, data for the last 4 years were analysed for the factors responsible for the histological severity of liver disease in patients with MASLD.
Results: The study included 400 biopsy-proven patients with MASLD [mean age 42 ± 11 years, mean BMI 27 ± 9 kg/m2, 258(64.5%) males]. Metabolic syndrome was present in 159(39.7%) of patients, T2DM was present in 93(23.3%) patients. The fibrosis stages were stage 0 in 114(28.5%), 1 in 130(32.5%), 2 in 73(18.3%), 3 in 35(8.8%) and 4 in 48(12%). Patients with advanced fibrosis (versus F0-F2) had higher age (46.6 ± 11.8 years versus 41.4 ± 11.4 years, P = 0.000), higher prevalence of T2DM [32/83, (38.6%) versus 61/317 (19.2%), P = 0.000)], female gender [40/83 (48.2%) versus 102/317 (32.2%), P = 0.010), triglycerides >150 mg/dl [20/83 (24.1%) versus 158/317 (49.8%), P = 0.000)] and lower HDL [64/83 (77.1%) versus 207/317 (65.3%), P = 0.048)]. The multivariate analysis model including age, gender and DM showed that age [OR 1.025 (95% CI 1.001-1.049, P = 0.042] and T2DM [OR 1.943 (95% CI 1.099-3.433, P = 0.022] were significant predictors of advanced fibrosis. A total of 32/93(34.4%) patients with T2DM had advanced fibrosis as compared to 51/307(16.6%) in the non-DM group (P = 0.000).
Conclusion: In comparison to those without T2DM, the risk of advanced fibrosis is almost twice in patients with MASLD and type 2 DM. Both higher age and T2DM were associated with advanced fibrosis in patients with MASLD.
背景：在非酒精性脂肪性肝病（NAFLD）患者中，糖尿病与肝纤维化之间的关系得到了很好的研究。随着最近术语和定义的变化，在代谢功能障碍相关的脂肪变性肝病（MASLD）患者中没有类似的数据。本研究旨在分析MASLD患者晚期纤维化（肝活检3期或4期）与2型糖尿病（T2DM）的关系。方法：在印度MASLD协会（ICOM-D）正在进行的一项包括30个中心的多中心研究中，分析了过去4年的数据，以确定导致MASLD患者肝脏疾病组织学严重程度的因素。结果：本研究纳入400例经活检证实的MASLD患者[平均年龄42±11岁，平均BMI 27±9 kg/m2, 258例（64.5%）男性]。159例（39.7%）患者存在代谢综合征，93例（23.3%）患者存在T2DM。纤维化分期为114例（28.5%）为0期，130例（32.5%）为1期，73例（18.3%）为2期，35例（8.8%）为3期，48例（12%）为4期。晚期纤维化患者（F0-F2）年龄较高（46.6±11.8岁vs 41.4±11.4岁，P = 0.000）， T2DM患病率较高[32/83 (38.6%)vs 61/317 (19.2%), P = 0.000)]，女性患病率较高[40/83 (48.2%)vs 102/317 (32.2%), P = 0.010]，甘油三酯bb0 150 mg/dl [20/83 (24.1%) vs 158/317 (49.8%), P = 0.000)]， HDL水平较低[64/83 (77.1%)vs 207/317 (65.3%), P = 0.048]。纳入年龄、性别和糖尿病的多因素分析模型显示，年龄[OR 1.025 (95% CI 1.001-1.049, P = 0.042]和T2DM [OR 1.943 (95% CI 1.099-3.433, P = 0.022]是晚期纤维化的显著预测因素。共有32/93(34.4%)T2DM患者发生晚期纤维化，而非dm组为51/307(16.6%)（P = 0.000）。结论：与没有T2DM的患者相比，MASLD和2型DM患者发生晚期纤维化的风险几乎是2倍。MASLD患者的高龄和T2DM均与晚期纤维化相关。
{"title":"Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) Study.","authors":"Narendra S Choudhary, Ajay Duseja, Arka De, Manu Mehta, S P Singh, Prajna Anirvan, Shrikant Mukewar, Sourabh Mukewar, Shalimar, Sanjib Kar, Omesh Goyal, Rakhi Maiwall, Jayanthi Venkataraman, Krishnadas Devadas, V K Dixit, Varun Mehta, Piyush Ranjan, Aabha Nagral, Anil Arora, Arun Valsan, Sunil Dadhich, Brij Sharma, Rohit Gupta, Sandeep Nijhawan, Akash Roy, Dibyalochan Praharaj, P N Rao, Akash Shukla, Rajiv Mehta, Pankaj Asati, Sanjeev Saigal, K Narayanasamy, Mallika Bhattacharya, V G M Prasad, Abraham Koshy, Mukul Rastogi, Seema Alam, Arun J Sanyal","doi":"10.1016/j.jceh.2025.103468","DOIUrl":"https://doi.org/10.1016/j.jceh.2025.103468","url":null,"abstract":"<p><strong>Background: </strong>The association between diabetes mellitus and liver fibrosis is well studied in patients with nonalcoholic fatty liver disease (NAFLD). With the recent change in nomenclature and definition, similar data are not available in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The present study aims to analyse the association of advanced fibrosis (stage 3 or 4 on liver biopsy) and type 2 diabetes mellitus (T2DM) in patients with MASLD.</p><p><strong>Methods: </strong>In an ongoing multicentre study of the Indian Consortium on MASLD(ICOM-D) including 30 centres, data for the last 4 years were analysed for the factors responsible for the histological severity of liver disease in patients with MASLD.</p><p><strong>Results: </strong>The study included 400 biopsy-proven patients with MASLD [mean age 42 ± 11 years, mean BMI 27 ± 9 kg/m<sup>2</sup>, 258(64.5%) males]. Metabolic syndrome was present in 159(39.7%) of patients, T2DM was present in 93(23.3%) patients. The fibrosis stages were stage 0 in 114(28.5%), 1 in 130(32.5%), 2 in 73(18.3%), 3 in 35(8.8%) and 4 in 48(12%). Patients with advanced fibrosis (versus F0-F2) had higher age (46.6 ± 11.8 years versus 41.4 ± 11.4 years, <i>P</i> = 0.000), higher prevalence of T2DM [32/83, (38.6%) versus 61/317 (19.2%), <i>P</i> = 0.000)], female gender [40/83 (48.2%) versus 102/317 (32.2%), <i>P</i> = 0.010), triglycerides >150 mg/dl [20/83 (24.1%) versus 158/317 (49.8%), <i>P</i> = 0.000)] and lower HDL [64/83 (77.1%) versus 207/317 (65.3%), <i>P</i> = 0.048)]. The multivariate analysis model including age, gender and DM showed that age [OR 1.025 (95% CI 1.001-1.049, <i>P</i> = 0.042] and T2DM [OR 1.943 (95% CI 1.099-3.433, <i>P</i> = 0.022] were significant predictors of advanced fibrosis. A total of 32/93(34.4%) patients with T2DM had advanced fibrosis as compared to 51/307(16.6%) in the non-DM group (<i>P</i> = 0.000).</p><p><strong>Conclusion: </strong>In comparison to those without T2DM, the risk of advanced fibrosis is almost twice in patients with MASLD and type 2 DM. Both higher age and T2DM were associated with advanced fibrosis in patients with MASLD.</p>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 2","pages":"103468"},"PeriodicalIF":3.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12887264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1016/j.jceh.2025.103465
Asisha M. Janeela , Gayathiri K. Chellaiya , Rohan Thomas , Alok Bansal , Snehil Kumar , Gnanadeepam Sunderraj , Sumathy Jayaraman , Santhosh E. Kumar , Vijay Alexander , Vinoi G. David , Santosh Varughese , Dolly Daniel , Sukesh C. Nair , Chundamannil E. Eapen , Ashish Goel , Uday G. Zachariah
Background/Aims
Centrifugal plasma exchange (PLEX), by virtue of low blood flow rates, can be performed via peripheral venous access. This study aims to assess the utilization, safety, and efficiency of low-volume centrifugal plasma exchange via peripheral venous access (P-PLEX) in liver disease patients.
Methods
This retrospective cohort study compared patients with liver disease who underwent low-volume centrifugal P-PLEX (2019–2024) with syndrome-matched patients who underwent plasma exchange via central venous access (C-PLEX). Data on PLEX procedure, venous access, and extraction efficiency for molecules of interest were noted.
Results
Of 448 liver disease patients who underwent centrifugal low-volume PLEX, 81 patients (18.1%) who underwent P-PLEX (M: 60; age: 37 [29.5–46.5] years; median, interquartile range) were compared with 81 syndrome-matched patients who underwent C-PLEX (M: 62; age: 37 [29.5–46.5] years; acute-on-chronic liver failure: 44, acute liver injury/acute liver failure: 21, others: 20). Targeted P-PLEX sessions were completed in 67 of 81 (82%). P-PLEX access was mostly 18-G (n = 64/72 for inlet/return) in antecubital fossa. Thirteen of 81 (16%) P-PLEX patients required access change to C-PLEX. Procedure time was longer in P-PLEX group (105 [82.5–120] min) than in the C-PLEX group (75 [60–91.3] min, P value< 0.001) due to lower flow rates in P-PLEX. When controlled for exchange volumes and baseline values, extraction efficiency of bilirubin (P-PLEX: 34.3% [21.2–42.6], C-PLEX: 27.1% [10.3–41.7]; P value: 0.14) and von Willebrand factor antigen (P-PLEX: 36.1% [21.8–46.8], C-PLEX: 45.6% [32.8–58.3]; P value: 0.19) were similar in both groups. PLEX was performed in the ward (in high monitoring area) in majority of patients in the P-PLEX group (73 [90.1%]) and in the high-dependency unit (43 [53.1%]) in the C-PLEX group. Lower line-related complications with P-PLEX (2/81) vis-à-vis C-PLEX (9/81, P-value: 0.03) were noted.
Conclusion
In this report, low-volume centrifugal PLEX to treat liver disease was performed via peripheral venous access in 18% of patients. P-PLEX was done in the ward, with similar efficiency and better line-related safety; however, the PLEX duration was prolonged by 30 min.
{"title":"Peripheral Venous Access for Low-Volume Centrifugal Plasma Exchange to Treat Patients With Liver Disorders","authors":"Asisha M. Janeela , Gayathiri K. Chellaiya , Rohan Thomas , Alok Bansal , Snehil Kumar , Gnanadeepam Sunderraj , Sumathy Jayaraman , Santhosh E. Kumar , Vijay Alexander , Vinoi G. David , Santosh Varughese , Dolly Daniel , Sukesh C. Nair , Chundamannil E. Eapen , Ashish Goel , Uday G. Zachariah","doi":"10.1016/j.jceh.2025.103465","DOIUrl":"10.1016/j.jceh.2025.103465","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Centrifugal plasma exchange (PLEX), by virtue of low blood flow rates, can be performed via peripheral venous access. This study aims to assess the utilization, safety, and efficiency of low-volume centrifugal plasma exchange via peripheral venous access (P-PLEX) in liver disease patients.</div></div><div><h3>Methods</h3><div>This retrospective cohort study compared patients with liver disease who underwent low-volume centrifugal P-PLEX (2019–2024) with syndrome-matched patients who underwent plasma exchange via central venous access (C-PLEX). Data on PLEX procedure, venous access, and extraction efficiency for molecules of interest were noted.</div></div><div><h3>Results</h3><div>Of 448 liver disease patients who underwent centrifugal low-volume PLEX, 81 patients (18.1%) who underwent P-PLEX (M: 60; age: 37 [29.5–46.5] years; median, interquartile range) were compared with 81 syndrome-matched patients who underwent C-PLEX (M: 62; age: 37 [29.5–46.5] years; acute-on-chronic liver failure: 44, acute liver injury/acute liver failure: 21, others: 20). Targeted P-PLEX sessions were completed in 67 of 81 (82%). P-PLEX access was mostly 18-G (n = 64/72 for inlet/return) in antecubital fossa. Thirteen of 81 (16%) P-PLEX patients required access change to C-PLEX. Procedure time was longer in P-PLEX group (105 [82.5–120] min) than in the C-PLEX group (75 [60–91.3] min, <em>P</em> value< 0.001) due to lower flow rates in P-PLEX. When controlled for exchange volumes and baseline values, extraction efficiency of bilirubin (P-PLEX: 34.3% [21.2–42.6], C-PLEX: 27.1% [10.3–41.7]; <em>P</em> value: 0.14) and von Willebrand factor antigen (P-PLEX: 36.1% [21.8–46.8], C-PLEX: 45.6% [32.8–58.3]; <em>P</em> value: 0.19) were similar in both groups. PLEX was performed in the ward (in high monitoring area) in majority of patients in the P-PLEX group (73 [90.1%]) and in the high-dependency unit (43 [53.1%]) in the C-PLEX group. Lower line-related complications with P-PLEX (2/81) vis-à-vis C-PLEX (9/81, <em>P</em>-value: 0.03) were noted.</div></div><div><h3>Conclusion</h3><div>In this report, low-volume centrifugal PLEX to treat liver disease was performed via peripheral venous access in 18% of patients. P-PLEX was done in the ward, with similar efficiency and better line-related safety; however, the PLEX duration was prolonged by 30 min.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 2","pages":"Article 103465"},"PeriodicalIF":3.2,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.1016/j.jceh.2025.103466
Sanish Ancil , Jahnvi Dhar , Rahul Thakur, Pankaj Gupta, Cherring Tandup, Satish S. Nagaraj, Saroj K. Sinha, Jayanta Samanta
{"title":"Endoscopic Ultrasound-Directed Trans-Gastric ERCP for Management of Choledocholithiasis in a Roux-en-Y Gastric Bypass Anatomy","authors":"Sanish Ancil , Jahnvi Dhar , Rahul Thakur, Pankaj Gupta, Cherring Tandup, Satish S. Nagaraj, Saroj K. Sinha, Jayanta Samanta","doi":"10.1016/j.jceh.2025.103466","DOIUrl":"10.1016/j.jceh.2025.103466","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 2","pages":"Article 103466"},"PeriodicalIF":3.2,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.jceh.2025.103464
Andreas Bartholdy , Pernille Y. Nielsen , Lise L. Gluud , Laust H. Mortensen , Birgitte M. Viuff , Elisabeth D. Galsgaard , Majken K. Jensen
Background/Aims
Steatotic liver disease (SLD) including metabolic dysfunction-associated and alcoholic liver disease, is the most prevalent chronic liver condition globally. Liver biopsy remains the gold standard for fibrosis assessment, but traditional staging is difficult even for highly skilled experts. Collagen proportionate area (CPA), a quantitative digital pathology measure, may offer an alternative, yet its prognostic value in population-based settings is unclear.
Methods
Liver biopsies from a cohort of 166 adults with biopsy-confirmed SLD, diagnosed between 1995 and 2008, were retrieved. The liver biopsies underwent fibrosis staging (stages F0–F4) by a pathologist and digital CPA quantification. Clinical outcomes and mortality were tracked via national registries over a median follow-up of 14.8 years. Associations between fibrosis stage, CPA, and all-cause mortality and liver-related events were assessed using Cox regression and cause-specific hazard models, adjusting for alcohol use and age. Predictive performance was evaluated with area under the receiver operating characteristic curve (AUC), index of prediction accuracy (IPA), and calibration plots, internally validated by bootstrapping.
Results
CPA correlated significantly with fibrosis stage (Spearman's ρ = 0.63), particularly in advanced fibrosis. Higher fibrosis stages and greater CPA were associated with increased all-cause mortality and liver-related events, but the associations for CPA were nonsignificant after adjustment for age and alcohol use. Scaled estimates of HRs from CPA were lower compared to HRs from fibrosis stages. Predictive models for mortality demonstrated comparable and moderate discrimination for CPA and fibrosis stage, improving with age adjustment. IPA values and calibration plots indicated positive predictive accuracy for mortality but poor performance for liver-specific outcomes.
Conclusions
CPA closely correlates with fibrosis stage and has comparable long-term prognostic value in SLD. Interpretation of study results is limited by the small sample size and low number of liver-specific events. Larger studies are needed to validate CPA's clinical utility and explore its integration into routine practice.
{"title":"Collagen Proportionate Area and Histological Grading of Fibrosis as Predictors of Clinical Outcomes and Mortality in Patients with Steatotic Liver Disease","authors":"Andreas Bartholdy , Pernille Y. Nielsen , Lise L. Gluud , Laust H. Mortensen , Birgitte M. Viuff , Elisabeth D. Galsgaard , Majken K. Jensen","doi":"10.1016/j.jceh.2025.103464","DOIUrl":"10.1016/j.jceh.2025.103464","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Steatotic liver disease (SLD) including metabolic dysfunction-associated and alcoholic liver disease, is the most prevalent chronic liver condition globally. Liver biopsy remains the gold standard for fibrosis assessment, but traditional staging is difficult even for highly skilled experts. Collagen proportionate area (CPA), a quantitative digital pathology measure, may offer an alternative, yet its prognostic value in population-based settings is unclear.</div></div><div><h3>Methods</h3><div>Liver biopsies from a cohort of 166 adults with biopsy-confirmed SLD, diagnosed between 1995 and 2008, were retrieved. The liver biopsies underwent fibrosis staging (stages F0–F4) by a pathologist and digital CPA quantification. Clinical outcomes and mortality were tracked via national registries over a median follow-up of 14.8 years. Associations between fibrosis stage, CPA, and all-cause mortality and liver-related events were assessed using Cox regression and cause-specific hazard models, adjusting for alcohol use and age. Predictive performance was evaluated with area under the receiver operating characteristic curve (AUC), index of prediction accuracy (IPA), and calibration plots, internally validated by bootstrapping.</div></div><div><h3>Results</h3><div>CPA correlated significantly with fibrosis stage (Spearman's ρ = 0.63), particularly in advanced fibrosis. Higher fibrosis stages and greater CPA were associated with increased all-cause mortality and liver-related events, but the associations for CPA were nonsignificant after adjustment for age and alcohol use. Scaled estimates of HRs from CPA were lower compared to HRs from fibrosis stages. Predictive models for mortality demonstrated comparable and moderate discrimination for CPA and fibrosis stage, improving with age adjustment. IPA values and calibration plots indicated positive predictive accuracy for mortality but poor performance for liver-specific outcomes.</div></div><div><h3>Conclusions</h3><div>CPA closely correlates with fibrosis stage and has comparable long-term prognostic value in SLD. Interpretation of study results is limited by the small sample size and low number of liver-specific events. Larger studies are needed to validate CPA's clinical utility and explore its integration into routine practice.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 2","pages":"Article 103464"},"PeriodicalIF":3.2,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jceh.2025.103467
Zhencheng Zhang, Zaixing Yang
{"title":"Characterization of Both CD24+ and CD24- T Cells can Better Elucidate the Influence of CD24 on Cytokine Production","authors":"Zhencheng Zhang, Zaixing Yang","doi":"10.1016/j.jceh.2025.103467","DOIUrl":"10.1016/j.jceh.2025.103467","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 2","pages":"Article 103467"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jceh.2025.103444
Vinay Jahagirdar, Ali Khan, Jasmohan S. Bajaj
{"title":"From Shunt to Strength: Toward an Indian Model of TIPS Prehabilitation","authors":"Vinay Jahagirdar, Ali Khan, Jasmohan S. Bajaj","doi":"10.1016/j.jceh.2025.103444","DOIUrl":"10.1016/j.jceh.2025.103444","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 1","pages":"Article 103444"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jceh.2025.103419
Nathkapach K. Rattanapitoon, Chutharat Thanchonnang, Patpicha Arunsan, Schawanya K. Rattanapitoon
{"title":"Beyond Genetic Protection: Revisiting Hepatic Resilience in Prader-Willi Syndrome","authors":"Nathkapach K. Rattanapitoon, Chutharat Thanchonnang, Patpicha Arunsan, Schawanya K. Rattanapitoon","doi":"10.1016/j.jceh.2025.103419","DOIUrl":"10.1016/j.jceh.2025.103419","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 1","pages":"Article 103419"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.jceh.2026.103483
{"title":"Issue Highlights","authors":"","doi":"10.1016/j.jceh.2026.103483","DOIUrl":"10.1016/j.jceh.2026.103483","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"16 1","pages":"Article 103483"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号